Literature DB >> 8491060

Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations.

J Hasselström1, J Säwe.   

Abstract

Morphine, morphine-6-glucuronide (M6G), morphine-3-glucuronide (M3G) and normorphine were analysed with high performance liquid chromatography in plasma and urine, collected over 72 h after administration of single intravenous 5 mg and oral 20 mg doses of morphine to 7 healthy volunteers. Systemic plasma clearance of morphine was on average 21.1 +/- 3.4 ml/min/kg (1.27 +/- 0.20 L/h/kg), volume of distribution was 2.9 +/- 0.8 L/kg and oral bioavailability was 29.2 +/- 7.2%. Clearance of morphine to form M3G and M6G comprised 57.3% and 10.4%, respectively, and renal clearance comprised 10.9% of total systemic plasma clearance; hence, more than one-fifth of a dose (20.8%) remained as unidentified residual clearance. On the basis of the area under the plasma concentration-time curves determined after oral and intravenous administration, the ratios of M6G:morphine were 3.6 +/- 1.2 and 0.7 +/- 0.3, respectively. The corresponding figures for M3G:morphine were 29.9 +/- 6.8 and 7.7 +/- 1.4. Differences in metabolic ratios between the parenteral and oral routes could be attributed solely to differences in morphine concentrations as evidenced both by plasma concentrations and amounts excreted in urine. An oral:parenteral potency ratio of 1:3 may, thus, be due to differences in circulating amounts of morphine since the proportions of an administered dose found as M6G and M3G after administration by both routes were equal. A major finding was a slowly declining terminal phase of morphine and metabolites that was evident both in plasma and in urinary excretion versus time curves, where the half-lives of morphine, M3G and M6G were 15.1 +/- 6.5 h, 11.2 +/- 2.7 h and 12.9 +/- 4.5 h, respectively. The terminal half-life of normorphine was 23.9 +/- 10.1 h after oral administration. Comparison of oral with intravenous excretion curves showed that a greater part of morphine and metabolites were excreted during the slowly declining phase after the oral dose than the intravenous dose, which is highly suggestive of enterohepatic cycling. The renal clearance of M6G and morphine was seen to exceed creatinine clearance, possibly due to an active secretion process.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8491060     DOI: 10.2165/00003088-199324040-00007

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  45 in total

1.  Long lasting respiratory depression induced by morphine-6-glucuronide?

Authors:  J Hasselström; U Berg; A Löfgren; J Säwe
Journal:  Br J Clin Pharmacol       Date:  1989-04       Impact factor: 4.335

Review 2.  The central and peripheral influences of opioids on gastrointestinal propulsion.

Authors:  L Manara; A Bianchetti
Journal:  Annu Rev Pharmacol Toxicol       Date:  1985       Impact factor: 13.820

3.  Enterohepatic circulation of indomethacin and its role in intestinal irritation.

Authors:  D E Duggan; K F Hooke; R M Noll; K C Kwan
Journal:  Biochem Pharmacol       Date:  1975-10-01       Impact factor: 5.858

4.  Estimation of area under the curve for drugs subject to enterohepatic cycling.

Authors:  T A Shepard; R H Reuning; L J Aarons
Journal:  J Pharmacokinet Biopharm       Date:  1985-12

5.  Urinary excretion of morphine and its metabolites in morphine-dependent subjects.

Authors:  S Y Yeh
Journal:  J Pharmacol Exp Ther       Date:  1975-01       Impact factor: 4.030

6.  Interindividual and interethnic differences in the demethylation and glucuronidation of codeine.

Authors:  Q Y Yue; J O Svensson; C Alm; F Sjöqvist; J Säwe
Journal:  Br J Clin Pharmacol       Date:  1989-12       Impact factor: 4.335

7.  Hepatic circulation during surgical stress and anesthesia with halothane, isoflurane, or fentanyl.

Authors:  S Gelman; E Dillard; E L Bradley
Journal:  Anesth Analg       Date:  1987-10       Impact factor: 5.108

8.  Morphine-6-glucuronide: effects on ventilation in normal volunteers.

Authors:  S J Peat; M H Hanna; M Woodham; A A Knibb; J Ponte
Journal:  Pain       Date:  1991-04       Impact factor: 6.961

9.  Kinetics and dynamics of postoperative intravenous morphine in children.

Authors:  K T Olkkola; E L Maunuksela; R Korpela; P H Rosenberg
Journal:  Clin Pharmacol Ther       Date:  1988-08       Impact factor: 6.875

Review 10.  High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment.

Authors:  J Säwe
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

View more
  50 in total

1.  Evidence for dissolution rate-limited absorption of COL-3, a matrix metalloproteinase inhibitor, leading to the irregular absorption profile in rats after oral administration.

Authors:  Jing Li; Hung Huynh; Eli Chan
Journal:  Pharm Res       Date:  2002-11       Impact factor: 4.200

Review 2.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

Review 3.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

4.  Morphine-6-O-beta-D-glucuronide but not morphine-3-O-beta-D-glucuronide binds to mu-, delta- and kappa- specific opioid binding sites in cerebral membranes.

Authors:  S V Löser; J Meyer; S Freudenthaler; M Sattler; C Desel; I Meineke; U Gundert-Remy
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-07       Impact factor: 3.000

Review 5.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

6.  In vivo-formed versus preformed metabolite kinetics of trans-resveratrol-3-sulfate and trans-resveratrol-3-glucuronide.

Authors:  Satish Sharan; Otito F Iwuchukwu; Daniel J Canney; Cheryl L Zimmerman; Swati Nagar
Journal:  Drug Metab Dispos       Date:  2012-07-17       Impact factor: 3.922

7.  Midazolam Dose Optimization in Critically Ill Pediatric Patients With Acute Respiratory Failure: A Population Pharmacokinetic-Pharmacogenomic Study.

Authors:  Athena F Zuppa; Daniela J Conrado; Nicole R Zane; Martha A Q Curley; Jonathan Bradfield; Hakon Hakonarson; Madeleine S Gastonguay; Ganesh Moorthy; Janice Prodell; Marc R Gastonguay
Journal:  Crit Care Med       Date:  2019-04       Impact factor: 7.598

8.  Morphine metabolite pharmacokinetics during venoarterial extra corporeal membrane oxygenation in neonates.

Authors:  Jeroen W B Peters; Brian J Anderson; Sinno H P Simons; Donald R A Uges; Dick Tibboel
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

9.  Effect of a Roux-en-Y gastric bypass on the pharmacokinetics of oral morphine using a population approach.

Authors:  Célia Lloret-Linares; Déborah Hirt; Christophe Bardin; Jean-Luc Bouillot; Jean-Michel Oppert; Christine Poitou; François Chast; Stéphane Mouly; Jean-Michel Scherrmann; Jean-François Bergmann; Xavier Declèves
Journal:  Clin Pharmacokinet       Date:  2014-10       Impact factor: 6.447

Review 10.  Pain treatment with opioids : achieving the minimal effective and the minimal interacting dose.

Authors:  Pierangelo Geppetti; Silvia Benemei
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.